Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of indolent B-cell non-Hodgkin's lymphoma of 1 of the following subtypes:
• * Follicular (grade 1, 2, or 3)
• * Marginal zone (extranodal, nodal, or splenic)
• CD20-positive disease
• Relapsed or progressive disease after prior anti-neoplastic therapy, as indicated by 1 of the following:
• * New lesions
• * Objective evidence of progression of existing lesions
• Complete response ≥ 6 months in duration after prior rituximab therapy\* NOTE: \*For patients who were previously treated with a regimen that included rituximab
• At least 1 measurable lymph node mass \> 1.5 cm in 2 perpendicular dimensions that has not been irradiated OR that has progressed since prior radiotherapy
• No active CNS lymphoma
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• Karnofsky 50-100% OR
• ECOG 0-2
• Life expectancy
• Not specified
• Hematopoietic
• Absolute neutrophil count ≥ 1,000/mm\^3
• Platelet count ≥ 50,000/mm\^3
• Hepatic
• AST and ALT ≤ 3 times upper limit of normal (ULN)
• Bilirubin ≤ 2 times ULN
• Renal
• Creatinine ≤ 2 mg/dL OR
• Creatinine clearance ≥ 30 mL/min
• Immunologic
• No known anaphylaxis or immunoglobulin E-mediated hypersensitivity to murine proteins or to any component of rituximab, including polysorbate 80 and sodium citrate dihydrate
• No active systemic infection requiring treatment
• No history of allergic reaction attributable to compounds containing boron or mannitol
• Other
• No peripheral neuropathy or neuropathic pain ≥ grade 2
• No other malignancy within the past 5 years except completely resected basal cell or squamous cell skin cancer or an in situ malignancy
• * Previously diagnosed prostate cancer allowed provided the following criteria are met:
• * T1-2a, N0, M0 disease AND Gleason score ≤ 7 AND prostate specific antigen (PSA) ≤ 10 ng/mL before initial therapy
• * Treated with definitive curative therapy (i.e., prostatectomy or radiotherapy) within the past 2 years
• * No clinical evidence of prostate cancer AND undetectable PSA (for prostatectomy patients) or PSA \< 1 ng/mL (for patients who did not undergo prostatectomy)
• No serious medical or psychiatric illness that would preclude study participation
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• See Disease Characteristics
• More than 10 weeks since prior radioimmunoconjugates or toxin immunoconjugates (e.g., ibritumomab tiuxetan or iodine I 131 tositumomab)
• More than 4 weeks since prior rituximab, alemtuzumab, or other unconjugated therapeutic antibody
• No concurrent prophylactic bone marrow growth factors (e.g., filgrastim \[G-CSF\], sargramostim \[GM-CSF\], or epoetin alfa) during course 1 of study therapy
• Chemotherapy
• More than 6 weeks since prior nitrosoureas
• No concurrent cisplatin
• Endocrine therapy
• No concurrent corticosteroids (e.g., dexamethasone) except prednisone ≤ 15 mg/day or equivalent for adrenal insufficiency
• Radiotherapy
• See Disease Characteristics
• See Biologic therapy
• More than 3 weeks since prior radiotherapy
• No concurrent radiotherapy
• Surgery
• More than 2 weeks since prior major surgery
• Other
• Recovered from all prior therapy
• No prior bortezomib
• More than 3 weeks since prior antineoplastic therapy
• More than 3 weeks since prior experimental therapy
• No other concurrent antineoplastic therapy
• No other concurrent investigational agents
• * Concurrent participation in a non-treatment study allowed provided it does not interfere with participation in this study